Pelelisa 1% cream is indicated for the topical treatment of plaque psoriasis in adult.
This cream contains Tapinarof as the active ingredient. Tapinarof is an Aryl hydrocarbon Receptor (AhR) agonist. The specific mechanisms by which Tapinarof cream exerts its therapeutic action in psoriasis patients are unknown.
Apply a thin layer of Tapinarof cream to affected areas once daily. Wash hands after application, unless Tapisis cream is for treatment of the hands. Tapinarof cream is not for oral, ophthalmic, or intravaginal use. Pediatric Use : Safety and efficacy of Tapinarof cream have not been established in pediatric subjects with psoriasis under 18 years of age.
Most common adverse reactions (incidence ≥ 1%) in subjects treated with Tapisis cream were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.
Hypersensitive to any of its components.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
No hazardous interactions have been reported with other medicines.
For external use only. Avoid use in eyes, oral or intravaginal use. If there is any unusual allergic reaction with the use of Pelelisa, then treatment should be discontinued and appropriate therapy should be instituted.